Supplemental Figures 1-6 from Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: Six supplemental Figures are included in this file. The figure titles are as follows: Supplemental Figure 1. Changes in G2/M cell cycle phase following treatment as a function of receptor status. Supplemental Figure 2. Downreguation of CDK1, CDK2 or both in ER positive cells. Supplemental Figure 3. Cell cycle analysis following single or combination treatments. Supplemental Figure 4. Sequential combination treatment of roscovitine and doxorubicin causes more DNA double strand breaks in p53 mutant in colon cancer cells. . Supplemental Figure 5. Sequential roscovitine-doxorubicin combination treatment is effective and well tolerated in vivo. Supplemental Figure 6 Dose escalation of doxorubicin in vivo
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362548324